These pieces of evidence support that PRC2 inhibitors could induce therapeutic response in cancer from different body location, and the combination of PRC2 inhibitor with PD-1 therapy and/or CDK4/6 inhibitors could be a valid clinic strategy. This evidence concerns the gene CDK4 and cancer.